Inovio Pharmaceuticals Total Assets

Inovio Pharmaceuticals posts a total assets of $50B as of March 2026. That compares with $87B in the prior-year period — down 43.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Inovio Pharmaceuticals's total assets was $87B. The latest reading is $50B — a 43.0% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of Inovio Pharmaceuticals's financial statement story. At $50B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for INO's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Inovio Pharmaceuticals's other metric pages and overview cover the third.

Judging Inovio Pharmaceuticals against Industrials peers is usually better than using a market-wide rule of thumb. Business models inside Industrials are more comparable, which makes gaps in total assets easier to interpret. Start with $50B here, then scan peer and history charts to see if the gap is persistent.